Notice: This company has been marked as potentially delisted and may not be actively trading. Immuron (IMRN) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsCompetitorsHeadlinesShort InterestTrends IMRN vs. SPRO, ELYM, FBIO, MDCX, VYNE, XLO, RAPT, OVID, KALA, and GBIOShould you be buying Immuron stock or one of its competitors? The main competitors of Immuron include Spero Therapeutics (SPRO), Eliem Therapeutics (ELYM), Fortress Biotech (FBIO), Medicus Pharma (MDCX), VYNE Therapeutics (VYNE), Xilio Therapeutics (XLO), RAPT Therapeutics (RAPT), Ovid Therapeutics (OVID), KALA BIO (KALA), and Generation Bio (GBIO). These companies are all part of the "pharmaceutical preparations" industry. Immuron vs. Spero Therapeutics Eliem Therapeutics Fortress Biotech Medicus Pharma VYNE Therapeutics Xilio Therapeutics RAPT Therapeutics Ovid Therapeutics KALA BIO Generation Bio Immuron (NASDAQ:IMRN) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their community ranking, analyst recommendations, valuation, profitability, media sentiment, risk, dividends, earnings and institutional ownership. Do insiders & institutionals believe in IMRN or SPRO? 0.1% of Immuron shares are owned by institutional investors. Comparatively, 25.6% of Spero Therapeutics shares are owned by institutional investors. 7.0% of Immuron shares are owned by insiders. Comparatively, 4.5% of Spero Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has more volatility & risk, IMRN or SPRO? Immuron has a beta of 1.38, indicating that its share price is 38% more volatile than the S&P 500. Comparatively, Spero Therapeutics has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500. Which has preferable earnings & valuation, IMRN or SPRO? Spero Therapeutics has higher revenue and earnings than Immuron. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmuron$3.21M3.30-$4.55MN/AN/ASpero Therapeutics$89.87M0.47$22.81M$0.0710.99 Is IMRN or SPRO more profitable? Spero Therapeutics has a net margin of 3.30% compared to Immuron's net margin of 0.00%. Spero Therapeutics' return on equity of 4.03% beat Immuron's return on equity.Company Net Margins Return on Equity Return on Assets ImmuronN/A N/A N/A Spero Therapeutics 3.30%4.03%2.21% Does the MarketBeat Community prefer IMRN or SPRO? Spero Therapeutics received 21 more outperform votes than Immuron when rated by MarketBeat users. Likewise, 69.67% of users gave Spero Therapeutics an outperform vote while only 67.87% of users gave Immuron an outperform vote. CompanyUnderperformOutperformImmuronOutperform Votes18867.87% Underperform Votes8932.13% Spero TherapeuticsOutperform Votes20969.67% Underperform Votes9130.33% Does the media refer more to IMRN or SPRO? In the previous week, Immuron had 1 more articles in the media than Spero Therapeutics. MarketBeat recorded 2 mentions for Immuron and 1 mentions for Spero Therapeutics. Spero Therapeutics' average media sentiment score of 0.62 beat Immuron's score of 0.00 indicating that Spero Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Immuron Neutral Spero Therapeutics Positive Do analysts recommend IMRN or SPRO? Immuron presently has a consensus price target of $5.00, suggesting a potential upside of 175.48%. Spero Therapeutics has a consensus price target of $5.00, suggesting a potential upside of 549.77%. Given Spero Therapeutics' higher possible upside, analysts plainly believe Spero Therapeutics is more favorable than Immuron.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immuron 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Spero Therapeutics 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 SummarySpero Therapeutics beats Immuron on 11 of the 16 factors compared between the two stocks. Get Immuron News Delivered to You Automatically Sign up to receive the latest news and ratings for IMRN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMRN vs. The Competition Export to ExcelMetricImmuronPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.03M$7.18B$5.79B$8.36BDividend YieldN/A2.80%4.89%3.97%P/E RatioN/A6.1424.8919.11Price / Sales3.30187.34373.96113.79Price / CashN/A65.6738.0534.62Price / Book1.246.417.334.26Net Income-$4.55M$138.98M$3.18B$246.62M Immuron Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMRNImmuron1.6977 of 5 stars$1.82-9.3%$5.00+175.5%+8.4%$11.03M$3.21M0.00N/ANews CoverageSPROSpero Therapeutics4.4994 of 5 stars$0.81-3.1%$5.00+521.0%-54.4%$43.89M$89.87M11.50150ELYMEliem TherapeuticsN/A$1.47+2.1%N/A-46.1%$43.74MN/A-2.779Gap DownFBIOFortress Biotech2.8183 of 5 stars$1.57-3.1%$13.67+770.5%-37.4%$43.34M$62.50M-0.51170News CoveragePositive NewsMDCXMedicus PharmaN/A$3.81-4.8%$10.00+162.5%N/A$41.34MN/A0.00N/AHigh Trading VolumeVYNEVYNE Therapeutics3.3651 of 5 stars$2.80+2.2%$6.88+145.5%+5.9%$41.30M$420,000.00-3.2630News CoverageXLOXilio Therapeutics2.9143 of 5 stars$0.94+1.0%$4.00+325.9%+25.6%$41.29MN/A-0.5570Gap DownRAPTRAPT Therapeutics4.0863 of 5 stars$1.18-5.6%$5.29+347.9%-88.3%$41.25M$1.53M-0.4380Upcoming EarningsNews CoverageOVIDOvid Therapeutics4.5746 of 5 stars$0.57-7.6%$4.03+607.1%-85.5%$40.50M$631,695.00-1.2160News CoverageKALAKALA BIO3.945 of 5 stars$6.64flat$15.00+125.9%-4.6%$40.44M$3.89M-0.5330Short Interest ↑Gap DownGBIOGeneration Bio3.2818 of 5 stars$0.60-1.0%$6.50+976.2%-79.5%$40.34M$5.90M-0.28150Upcoming EarningsGap Down Related Companies and Tools Related Companies SPRO Competitors ELYM Competitors FBIO Competitors MDCX Competitors VYNE Competitors XLO Competitors RAPT Competitors OVID Competitors KALA Competitors GBIO Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IMRN) was last updated on 3/4/2025 by MarketBeat.com Staff From Our Partners77 Hedge Funds Are Betting On This Off-Radar MineralWith surging prices... supply shortages... and growing demand, hedge funds are betting big on potash. In fa...The Tomorrow Investor | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredCollect $7k per month from Tesla’s SECRET dividendThere's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a tra...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immuron Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Immuron With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
